Carboxyamidotriazole orotate

Drug Profile

Carboxyamidotriazole orotate

Alternative Names: CAI orotate; CTO

Latest Information Update: 20 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tactical Therapeutics
  • Developer Duke University Medical Center; Tactical Therapeutics
  • Class Amides; Antineoplastics; Small molecules; Triazoles
  • Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Calcium channel antagonists; Cyclo-oxygenase 2 inhibitors; Epidermal growth factor receptor antagonists; Growth inhibitors; Interleukin 2 inhibitors; Nitric oxide synthase type I inhibitors; Phosphotransferase inhibitors; Proto oncogene protein c-akt inhibitors; Ras signal transduction pathway inhibitors; Vascular endothelial growth factor A expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Glioma
  • No development reported Age-related macular degeneration; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Glioma(Combination therapy, Newly diagnosed) in USA (PO)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO)
  • 14 Jun 2016 Duke University and Tactical Therapeutics terminate a phase I/II trial for Glioma (Recurrent disease, Second-line therapy or greater) in USA (NCT01989052)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top